An interventional study of Contingency Management in Methamphetamine Abuse, sponsored by University of California, Los Angeles. Completed at 1 site in South Africa. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-10.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment
This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.
This study will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within frontostriatal circuitry from baseline to end of the 8-week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes and (2) to determine whether structural changes in frontostriatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures.
University of California, Los Angeles is the lead sponsor of 1,167 studies on the registry; 192 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 69 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
Behavioral: Contingency Management
as described above
Responses to Contingency Management
urine samples documenting methamphetamine abstinence
Time frame: 8 weeks
fMRI Measures
measures of resting state connectivity
Time frame: Change b/w baseline and 8 Weeks
Stop Signal Task
measure of inhibitory control
Time frame: Change b/w baseline and 8 Weeks
Continuous Performance Task
test of sustained attention
Time frame: Change b/w baseline and 8 Weeks
Stroop
test of inhibitory control
Time frame: Change b/w baseline and 8 Weeks
Balloon Analog Risk Task
measure of risk taking and decision making
Time frame: Change b/w baseline and 8 Weeks
Plan to share: Yes — Data will be shared with other investigators following publication of the main paper or 2 years after the last subject completes participation, whichever comes first. Shared data will be stripped of all PHI and potentially personally identifying variables. Requests should briefly state the concept of interest, provide a brief timeline for analyzing the data and preparing a manuscript, and include a copy of the CV of the investigator making the request and documentation of proof of training in the ethical treatment of human subjects in research. The concept proposal will be evaluated based on three criteria, including the potential impact or contribution to the research in advancing knowledge; the feasibility of the proposed research; and that the aim of the proposed research will not overlap with any of the aims or planned analyses.
No publications or documents are linked to this record.
Ran from Sep 2015 to primary completion in Feb 2018, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →